Gastrointestinal Cancer | Specialty

Dr. Kopetz on the Significance of Tumor Sidedness in CRC

May 13th 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the significance of tumor sidedness in colorectal cancer.

The Future of HCC Management

May 13th 2019

The TARE IO and TACE IO Combination Therapies

May 13th 2019

The CheckMate 9DX and EMERALD 1 and 2 Trials

May 13th 2019

Systemic Plus Locoregional Combination Therapy in HCC

May 13th 2019

FDA Approves Second-Line Ramucirumab in AFP-Elevated HCC

May 11th 2019

The FDA has approved ramucirumab (Cyramza) monotherapy for patients with hepatocellular carcinoma who have an alpha fetoprotein of ≥400 ng/ML and have been previously treated with sorafenib.

Bounty of New HCC Therapies Spurs Need for More Research

May 10th 2019

The optimal integration of new drugs into the treatment paradigm of HCC requires several key developments, including greater research into biomarkers that would help inform therapy choices, earlier treatment for patients diagnosed with HCC, and clinical trials that test combination strategies.

Dr. Shields Discusses the Prevalence of Genetic Testing in CRC

May 9th 2019

Anthony Shields, MD, PhD, professor, Department of Oncology, Molecular Imaging and Diagnostics Program, Karmanos Cancer Institute, discusses the prevalence of genetic testing colorectal cancer.

Dr. Philip on FOLFIRINOX in Locally Advanced Pancreatic Cancer

May 9th 2019

Philip A. Philip, MD, PhD, FRCP, professor, Department of Oncology, Karmanos Cancer Institute, discusses the use of FOLFIRINOX in patients with locally advanced pancreatic cancer.

Vaccine Shows Signs of Stimulatory Effects in Early-Stage CRC

May 8th 2019

A vaccine targeting GUCY2C, a commonly overexpressed protein in patients with early-stage colorectal cancer, induced antibody and T-cell responses toward the specified target and demonstrated an acceptable safety profile in this patient population

Navigating the Complexities of Tumor Sidedness in Colorectal Cancer

May 7th 2019

Scott Kopetz, MD, PhD, FACP, explains the biologic difference between left- and right-sided colorectal cancer and highlights recent research on tumor sidedness and its impact on clinical practice.

Systemic Treatments for NETs: Whom to Treat and How to Sequence

May 2nd 2019

During a recent panel discussion, neuroendocrine tumor experts Simron Singh, MD, MPH, and Jonathan R. Strosberg, MD, provided insight on which patients are the best candidates for these approved treatments and how to sequence therapy to optimize outcomes.

Dr. Anthony on Sequencing Strategies for Patients With NETs

May 2nd 2019

Lowell B. Anthony, MD, FACP, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses sequencing strategies for patients with gastroenteropancreatic neuroendocrine tumors.

Dr. Mahipal on Molecular Markers in mCRC

May 2nd 2019

Amit Mahipal, MBBS, senior associate consultant, Division of Medical Oncology, Department of Oncology, associate professor of oncology, Mayo Clinic, discusses emerging molecular markers in patients with metastatic colorectal cancer (mCRC).

NETs Treatment Arsenal Expands, With More Progress on the Horizon

May 1st 2019

Lowell B. Anthony, MD, FACP, sheds light on important data that have shaped the current neuroendocrine tumors treatment paradigm and highlights notable ongoing studies.

Dr. Kim on the Potential of Ramucirumab in Advanced HCC

April 26th 2019

Richard Kim, MD, assistant professor of oncology at University of South Florida College of Medicine, medical oncologist in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses the potential of ramucirumab in the treatment of advanced hepatocellular carcinoma.

Dr. Overman on Tailoring Approaches to Molecular Subsets in mCRC

April 26th 2019

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses tailoring approaches to molecular subsets of patients with metastatic colorectal cancer.

Pembrolizumab/Chemo Combo Misses OS Endpoint in Advanced Gastric/GEJ Cancer

April 26th 2019

The combination of pembrolizumab (Keytruda) and chemotherapy did not improve overall survival or progression-free survival compared with standard chemotherapy alone for the frontline treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Dr. O'Hara on the Rationale for APX005M in Combination With Chemotherapy and Nivolumab in Pancreatic Cancer

April 26th 2019

Mark H. O’Hara, MD, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the rationale for evaluating APX005M in combination with chemotherapy and nivolumab (Opdivo) in pancreatic cancer.

Dr. Binder on Data Regarding Rucaparib Maintenance in Pancreatic Cancer

April 25th 2019

Kim A. Reiss Binder, MD, assistant professor of medicine in the Division of Hematology Oncology at the University of Pennsylvania, discusses data on maintenance therapy with rucaparib (Rubraca) in patients with pancreatic cancer.